Overview

Evaluate, Safety and Tolerability of Intraprostatic PRX302 Administration, Low to Intermediate Risk Prostate Cancer

Status:
Completed

Trial end date:
2016-06-01

Target enrollment:

Participant gender:

Summary

To Evaluate Safety, Tolerability and Potential Efficacy of PRX302 effect on clinically significant localised low to intermediate prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Sophiris Bio Corp